Marketing Analysis and Consumer Characteristics of Antihypertensive Drugs in the Azerbaijani Pharmaceutical Market
##semicolon##
https://doi.org/10.69760/portuni.26060009##semicolon##
Antihypertensive drugs##common.commaListSeparator## consumer behavior##common.commaListSeparator## arterial hypertension##common.commaListSeparator## pharmaceutical marketing##common.commaListSeparator## effectiveness##common.commaListSeparator## price–quality ratio##common.commaListSeparator## treatment adherence##common.commaListSeparator## pharmaceutical market##common.commaListSeparator## socio-economic factors##common.commaListSeparator## consumer profileSantrauka
The marketing characteristics and consumer behavior of antihypertensive drugs in the Azerbaijani pharmaceutical market were comprehensively analyzed. The study employed the content-analysis method, surveys conducted among physicians and end-users, and official statistical sources, including the state drug registry, the price lists of the Tariff Council, and data from the Analytical Expertise Center. The results indicate that preparations belonging to anatomical-therapeutic-chemical groups C03, C07, C08, and C09 dominate the market, with drugs acting on the renin-angiotensin system and their combinations occupying the leading position. Analysis of both physician and patient behavior revealed that therapeutic effectiveness and price are the principal criteria in drug selection. At the same time, poor treatment adherence, limited drug availability, and price level were identified as the key challenges in the management of arterial hypertension. The consumer-profile analysis demonstrates that the “effect–cost” balance plays a decisive role in the decision-making process, and that socio-economic factors significantly influence consumer behavior. The findings have practical implications for pharmaceutical companies, healthcare providers, and policymakers seeking to improve the accessibility, affordability, and rational use of antihypertensive therapy in Azerbaijan.
##submission.citations##
Baxşəliyev, A. B. (2018). Kliniki farmakologiya [Clinical pharmacology]. Ləman Nəşriyyat Poliqrafiya.
Grand View Research. (2025). Cardiovascular treatment market size, share & trends report (2025–2033). Grand View Research.
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., … Kjeldsen, S. E. (2023). 2023 ESH guidelines for the management of arterial hypertension. Journal of Hypertension, 41(12), 1874–2071. https://doi.org/10.1097/HJH.0000000000003480
Meher, M., Pradhan, S., & Pradhan, S. R. (2023). Risk factors associated with hypertension in young adults: A systematic review. Cureus, 15(4), e37467.
Vəliyeva, M. N., & Cabbarova, Ş. A. (2013). Əczaçılığın idarəolunması və iqtisadiyyatı [Pharmaceutical management and economics]. Şərq-Qərb Nəşriyyat Evi.
World Health Organization. (2021). Guideline for the pharmacological treatment of hypertension in adults. World Health Organization.
World Health Organization. (2023). Global report on hypertension: The race against a silent killer. World Health Organization.
##submission.downloads##
Publikuota
Numeris
Skyrius
##submission.license##
##submission.license.cc.by4.footer##Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows others to share, adapt, and build upon the work for any purpose, provided appropriate credit is given to the original author(s) and source. Authors are permitted to enter into separate agreements for non-exclusive distribution of the published version (e.g., post to a repository or publish in a book), with acknowledgement of its initial publication in this journal.